We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current FDMT market cap is 467.7M. The company's latest EPS is USD -1.9403 and P/E is -4.56.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 240k | 20.2M | -19k | 28k | 5k |
Operating Income | -32.14M | -13.97M | -36.65M | -38.14M | -42.46M |
Net Income | -29.62M | -10.26M | -32.28M | -32.4M | -34.95M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M |
Operating Income | -50.76M | -56.66M | -71.33M | -110.03M | -112.87M |
Net Income | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 352.5M | 361.61M | 339.89M | 629.88M | 620.12M |
Total Liabilities | 27.36M | 31.68M | 32.06M | 29.32M | 31.78M |
Total Equity | 325.14M | 329.93M | 307.83M | 600.56M | 588.34M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 58.23M | 288.33M | 353.49M | 261.85M | 339.89M |
Total Liabilities | 131.2M | 31.94M | 34.38M | 30.51M | 32.06M |
Total Equity | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -49.97M | -51.14M | -75.79M | -29.09M | -59.33M |
Investing | 92.42M | 122.4M | 115.72M | -263.26M | -336.8M |
Financing | 141.51M | 152.07M | 156.83M | 318.83M | 336.08M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M |
Investing | -3.2M | -1M | -172.68M | -17.05M | 115.72M |
Financing | -2.2M | 278.98M | 118.09M | 3.09M | 156.83M |
Market Cap | 467.7M |
Price to Earnings Ratio | -4.56 |
Price to Sales Ratio | 22.19 |
Price to Cash Ratio | 1.85 |
Price to Book Ratio | 1.49 |
Dividend Yield | - |
Shares Outstanding | 51.97M |
Average Volume (1 week) | 886.11k |
Average Volume (1 Month) | 784.53k |
52 Week Change | -18.26% |
52 Week High | 36.25 |
52 Week Low | 7.32 |
Spread (Intraday) | 9.5 (61.29%) |
Company Name | 4D Molecular Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.4dmoleculartherapeutics.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions